immatics biotechnologies GmbH Asset Resilience Ratio
immatics biotechnologies GmbH asset resilience ratio. immatics biotechnologies GmbH (4A3) has an Asset Resilience Ratio of 33.12% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See immatics biotechnologies GmbH defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of immatics biotechnologies GmbH (2019–2025)
Asset resilience ratio of immatics biotechnologies GmbH from 2019 to 2025. This chart shows how immatics biotechnologies GmbH's Asset Resilience Ratio has changed over time. Read how much debt does immatics biotechnologies GmbH carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down immatics biotechnologies GmbH's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 4A3 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €160.89 Million | 33.12% |
| Total Liquid Assets | €160.89 Million | 33.12% |
Asset Resilience Insights
- Very High Liquidity: immatics biotechnologies GmbH maintains exceptional liquid asset reserves at 33.12% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
immatics biotechnologies GmbH Industry Peers by Asset Resilience Ratio
Compare immatics biotechnologies GmbH's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
immatics biotechnologies GmbH Asset Resilience Ratio by Year (2019–2025)
immatics biotechnologies GmbH asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for immatics biotechnologies GmbH.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 21.95% | €123.42 Million ≈ $144.29 Million |
€562.34 Million ≈ $657.43 Million |
-30.87pp |
| 2024-12-31 | 52.82% | €367.70 Million ≈ $429.88 Million |
€696.15 Million ≈ $813.87 Million |
+12.15pp |
| 2023-12-31 | 40.67% | €207.42 Million ≈ $242.50 Million |
€509.96 Million ≈ $596.20 Million |
-11.72pp |
| 2022-12-31 | 52.40% | €213.69 Million ≈ $249.82 Million |
€407.82 Million ≈ $476.78 Million |
+45.46pp |
| 2021-12-31 | 6.94% | €12.12 Million ≈ $14.17 Million |
€174.65 Million ≈ $204.18 Million |
-2.66pp |
| 2020-12-31 | 9.60% | €24.45 Million ≈ $28.58 Million |
€254.65 Million ≈ $297.71 Million |
-2.33pp |
| 2019-12-31 | 11.93% | €16.02 Million ≈ $18.73 Million |
€134.28 Million ≈ $156.98 Million |
-- |
About immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecific… Read more